Navigation Links
Pancreas-targeted siRNA In Vivo Transfection Kit from Altogen Biosystems
Date:3/6/2012

LAS VEGAS, March 6, 2012 /PRNewswire/ -- Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals. This in vivo reagent is designed for targeted siRNA delivery into pancreas, however it is also compatible for transfection of any negatively charged molecules including RNA, DNA, proteins, and small molecules.

The pancreas is very important hormone-secreting organ in the human body. Pancreatic diseases include: Diabetes, pancreatitis, cystic fibrosis, and neoplasms. Pancreatic cancer is the fourth leading cause of cancer death in the United States with a lowest survival rate of its victims than any other form of cancer. Researchers in diabetes, pancreatic cancer, and other pancreas disorders, are focused on discovering and developing new therapeutics for patients. Testing novel compounds require efficient and targeted delivery of pharmaceuticals into pancreas tissue (known as in vivo transfection).

Pancreas-targeted siRNA In Vivo Transfection Kit enables researchers to utilize in vivo transfection method to introduce DNA, RNA, and other molecules into pancreas cells. This liposome-based technology makes it possible to cross the cellular barriers and deliver genetic material, or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.  Highly efficient targeted delivery of biomolecules to pancreas tissue is achieved via multiple administration routes: intravenous, intratumoral, intraperitoneal, or subcutaneous.

About Altogen Biosystems

Altogen Biosystems (www.altogen.com) is a life sciences company located in Las Vegas, Nevada. Altogen Biosystems specializing in the development of pre-optimized in vitro transfection reagents and in vivo delivery systems, transfection products and services. Altogen Labs (www.altogenlabs.com) is a GLP-compliant laboratory contract research organization.  The company offers pre-clinical research and biology CRO services including: xenograft animal models (cancer), cryopreservation and cell banking services, generation of stable cell lines, gene silencing RNAi services, tissue-targeted in vivo siRNA and DNA delivery services, custom liposome encapsulation, and cell-based assay development. 

Link: Pancreas-targeted siRNA In Vivo Transfection Kit  - http://www.altogen.com/Pancreas-In-Vivo-Transfection-Reagent-mouse-rat-tumor-animal-model-sirna-dna-protein-pancreas-invivo-delivery.php


'/>"/>
SOURCE Altogen Biosystems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
4. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
9. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
10. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):